galectintherapeutics.com (GALT) - Long-Term Debt to Capital Coefficient
Galectin Therapeutics (GALT) is establishing a closed therapeutic environment to combat cirrhosis, leveraging patent-protected methods. The biotech project is developing unique molecules for tissue regeneration in cancer and fibrosis. The market value dynamics of the asset at the 0.00 level are visualized below. The stability of the R&D team and the targeted hiring of administrators for clinical trials serve as key drivers for the company's future growth.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_GALT_-_Galectin-Therapeutics_-_Long-Term-Debt-to-Capital "GALT: Galectin Long-Term Debt to Capital 07/04/2022 - 10/30/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Galectin Therapeutics, Inc. (GALT)
For the single-product biotech Galectin Therapeutics (GALT), the long-term debt-to-equity ratio is critically important, as the funding for a single drug's trials determines the business's survival. This ratio, calculated as the proportion of loans with a maturity exceeding one year to total equity, measures the company's dependence on external borrowings and assesses the risk of insolvency should clinical tests be delayed.